BAYER AKTIENGESELLSCHAFT 4
4 · Senti Biosciences, Inc. · Filed Dec 11, 2024
Insider Transaction Report
Form 4
BAYER HEALTHCARE LLC
10% Owner
Transactions
- Purchase
Series A Convertible Preferred Stock
2024-12-09+2,222→ 2,222 total→ Common Stock (2,222,000 underlying) - Purchase
Warrant
2024-12-09+3,333,000→ 3,330,000 totalExercise: $2.30Exp: 2029-12-09→ Common Stock (3,333,000 underlying)
Holdings
- 587,848
Common Stock
Footnotes (4)
- [F1]The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is indirectly controlled by Bayer US Holding LP ("BUSH LP"), a Delaware limited partnership. Bayer World Investments B.V. ("BWI"), a Dutch private limited company, is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC.
- [F2]Each share of Series A Convertible Preferred Stock ("Series A") will convert into 1,000 shares of the Issuer's common stock upon the date that the Issuer's stockholders first approve the issuance of the Issuer's common stock upon conversion of the shares of Series A.
- [F3]The reported securities include shares of Series A and warrants purchased by the reporting person for $2,250 per unit. Each unit consists of one share of Series A, convertible into 1,000 shares of the Issuer's common stock, and accompanying warrant coverage to purchase 1,500 shares of the Issuer's common stock for each share of Series A purchased.
- [F4]The warrant becomes exercisable once the Issuer's stockholders first approve the issuance of the Issuer's common stock underlying the warrants in excess of the limitations imposed by Rule 5635 of the Nasdaq Stock Market listing rules.